The aim of this exploratory study was to evaluate whether the ER status of liver metastases in patients with breast cancer can be assessed with [18F]-FES-PET, using the ER expression measured immunohistochemically in corresponding tumor liver biopsies as the gold standard. This evidence concerns the gene ESR1 and neoplasm.